When Transfer to women and children on AndroGel (testosterone topical) Becomes a Reason to Stop

At a glance

• Incidence in trials: The key AndroGel 1% trial (Swerdloff et al., 2000) did not formally measure transfer events, but subsequent pharmacokinetic studies confirmed that a 100 mg dose leaves detectable residue on skin for up to 2 hours post-application without washing. FDA label revision in 2009 added a Black Box Warning after pediatric virilization cases were reported to MedWatch.
• Typical timeline to signs in exposed individuals: Children exposed repeatedly can show pubic hair, clitoral or penile enlargement, and accelerated bone age within 3 to 6 months of ongoing contact. Women typically show acne, clitoral enlargement, or menstrual irregularity within 4 to 12 weeks of consistent skin-to-skin contact.
• First-line management: Strict application-site washing before contact, application-site covering with clothing, and timing application to minimize contact windows.
• When to escalate: Any detectable sign of virilization in a household member, any serum testosterone above the upper limit of normal for age and sex in an exposed individual, or two confirmed transfer events despite correct application hygiene.
• When to discontinue: Confirmed virilization in any household member. Failed prevention after documented counseling and re-education. Patient or household circumstances that make reliable prevention structurally impossible.

Why Transfer Is Not Just a Label Warning

The FDA did not add the Black Box Warning for AndroGel transfer as a precautionary formality. Between 2002 and 2009, the agency received case reports of prepubertal children developing pubic hair, clitoral hypertrophy, penile enlargement, and advanced bone age after living with AndroGel users. In one well-characterized case series published by Kunz et al. (2004), two boys aged 4 and 5 showed Tanner stage 2 to 3 pubic hair development and significantly advanced bone maturation. Both cases resolved partially after the father discontinued the gel, but bone age advancement is not fully reversible once it occurs.

This is the clinical reality that separates transfer risk from most other TRT side effects. The harm does not fall on the patient. It falls on a child who cannot consent and cannot protect themselves, or on a female partner who may not connect her symptoms to a medication her partner is using.

What Counts as a Transfer Event

A transfer event has occurred when any of the following is confirmed:

In children: Any new-onset virilization sign (pubic, axillary, or facial hair; genital enlargement; acne; voice deepening; accelerated linear growth with advanced bone age on X-ray). Serum total testosterone above 10 ng/dL in a prepubertal child, or above the established Tanner-stage range for an adolescent, in the absence of another explanation.

In premenopausal women: Serum total testosterone above 70 to 80 ng/dL (depending on laboratory reference range), new-onset acne, clitoral enlargement, menstrual disruption, or hirsutism. The Endocrine Society's 2010 androgen therapy guideline explicitly notes that serum testosterone in women should remain within the physiologic premenopausal range and that values persistently above that threshold require source investigation.

In postmenopausal women: Any measurable elevation in total testosterone above laboratory upper limits for postmenopausal females, combined with any symptom.

A single confirmed transfer event with documented signs or lab abnormalities is, by itself, sufficient clinical justification to escalate management. Two confirmed events, or one event with irreversible signs such as bone age advancement, cross the threshold into discontinuation territory.

The Severity Spectrum: What Drives the Decision

Not every transfer situation calls for immediate discontinuation. The decision should scale with severity.

Mild (prevention counseling is appropriate): No clinical signs in household members. Serum testosterone in exposed individuals is within normal limits on one-time check. Transfer occurred because of a specific, correctable lapse (patient applied gel and then immediately picked up a child before washing hands).

Moderate (add monitoring, reinforce prevention, set a decision deadline): Lab elevation in an exposed individual without clinical signs. Acne or minor menstrual irregularity in a female partner without genital changes. Patient reports difficulty consistently following prevention steps due to work schedule, living situation, or caregiving demands.

Severe (discontinue AndroGel): Any genital change in a child or adult woman. Bone age advancement on skeletal survey. Serum testosterone in a child above 10 ng/dL or in a woman persistently above 80 ng/dL. Any transfer event that occurred despite the patient correctly following all FDA-recommended prevention steps, because if the steps are being followed and transfer still occurs, the formulation is not compatible with the household. FDA guidance on androgen products and secondary exposure makes clear that the burden of preventing harm to household members rests on the prescriber and patient together.

Time on Drug Before Stopping: Does Duration Matter?

A patient who has been on AndroGel for 6 years with no transfer events and a new infant in the household is in a different situation than a patient who is 3 months into treatment with an already-virilized child. Duration matters for two reasons.

First, a patient with a long, clean prevention record has demonstrated that their specific household situation is compatible with safe gel use. A targeted re-education session, a change in application timing, or a change in application site may be sufficient. Second, stopping testosterone abruptly after years of therapy can produce symptomatic hypogonadism. Fatigue, depression, low libido, and reduced bone density can all worsen in the weeks after discontinuation if no bridge therapy is arranged.

However, duration of use does not buy the patient tolerance for ongoing household exposure. A 6-year veteran who produces a confirmed transfer event today should not continue AndroGel without a concrete plan, even if the transfer event appears minor. The Endocrine Society clinical practice guideline on male hypogonadism (2018) notes that choice of formulation should account for patient circumstances including the presence of children or female partners at risk of inadvertent exposure.

What to Switch To

Switching is not a therapeutic failure. It is a clinically appropriate formulation change. Several alternatives carry zero transfer risk because they do not deposit testosterone on accessible skin surfaces.

Intramuscular testosterone (testosterone cypionate or enanthate): Injected into muscle every 1 to 2 weeks. No skin residue. Cost is low, efficacy is well established, and the pharmacokinetics are predictable. The trade-off is injection discomfort and a peak-and-trough serum level curve that some patients find symptomatic at troughs.

Subcutaneous pellet implants (Testopel): Inserted every 3 to 6 months under the skin of the buttock or flank. No skin residue. Delivers steady serum levels. Requires a minor in-office procedure and cannot be easily removed if levels are supraphysiologic.

Nasal testosterone gel (Natesto): Applied intranasally three times daily. Minimal systemic skin deposition. Serum levels are lower than with standard gels, which may be insufficient for some patients but eliminates the transfer mechanism entirely. A 2015 pharmacokinetic study of Natesto confirmed no measurable transfer to female partners.

Testosterone undecanoate injection (Aveed): Given every 10 weeks after two loading doses. No skin residue. Requires administration in a clinical setting due to pulmonary oil microembolism risk, which limits convenience but eliminates household transfer entirely.

When switching, the prescriber should plan the first injection or procedure to coincide with or closely follow the last AndroGel application to minimize a hypogonadal gap. Serum testosterone should be rechecked 4 to 6 weeks after the switch to confirm therapeutic levels.

Quality-of-Life Considerations for the Whole Household

It is worth acknowledging that the decision to stop AndroGel is not purely biochemical. Patients on TRT often report meaningful improvements in energy, mood, and sexual function. Discontinuation or formulation change carries real quality-of-life stakes for them.

At the same time, a partner experiencing new acne, irregular periods, or clitoral discomfort carries her own quality-of-life burden. A child undergoing premature virilization faces potential bone-growth disruption and significant psychological distress. The prescriber's obligation extends beyond the patient whose name is on the prescription.

The most honest framing for this conversation: AndroGel is not the only effective TRT option. If it cannot be used safely in a given household, the correct clinical response is to find the formulation that can.

---

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

• Swerdloff RS, Wang C, Cunningham G, et al. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab. 2000;85(12):4500-4510. https://pubmed.ncbi.nlm.nih.gov/11134099/
• Kunz GJ, Klein KO, Clemons RD, Gottschalk ME, Jones KL. Virilization of young children after topical androgen use by their parents. Pediatrics. 2004;114(1):282-284. https://pubmed.ncbi.nlm.nih.gov/15060213/
• FDA Drug Safety Communication: AndroGel and testosterone gel products. Secondary exposure to testosterone. 2009. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-safety-labeling-changes-testosterone-products
• Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. https://academic.oup.com/jcem/article/103/5/1715/4939465
• Wierman ME, Arlt W, Basson R, et al. Androgen therapy in women: A reappraisal. J Clin Endocrinol Metab. 2014;99(10):3489-3510. https://academic.oup.com/jcem/article/99/10/3489/2836481
• Rogol AD. New approaches to testosterone therapy for men with hypogonadism, including discussion of Natesto pharmacokinetics. J Clin Endocrinol Metab. 2015. Natesto prescribing information. https://pubmed.ncbi.nlm.nih.gov/25942654/
• AndroGel (testosterone gel) 1% and 1.62% Prescribing Information. AbbVie Inc. Current label with Black Box Warning. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021015s042lbl.pdf